The Mini-TRH Test

Abstract

Thyrotropin-releasing hormone (TRH), at doses lower than those needed to stimulate prolactin secretion directly, can almost completely antagonize dopamine inhibition of prolactin release. In normal men, prolactin increases 15 min following an i. v. bolus of 12.5 µg TRH (the mini-TRH test), but not the maximal prolactin response to TRH or basal prolactin, positively correlated with prolactin response to haloperidol and negatively with 24-h urinary excretion of homovanillic acid (HVA). These results suggest that the mini-TRH test is a better estimate of dopamine inhibition of prolactin release than the maximal prolactin response or basal prolactin level. A recent neuroimaging study suggested that in schizophrenia, there is a widely distributed defect in extrastriatal dopamine release, but the patients were not in the most acute phase of psychosis. The evidence is reviewed that this defect extends to tuberoinfundibular dopamine (TIDA) and which symptoms are associated with the test. In patients with acute nonaffective psychosis, the mini-TRH test positively correlated with nonparanoid delusions and memory dysfunction, indicating decreased dopamine transmission in association with these symptoms. In patients with acute drug-naïve first-episode schizophrenia, the mini-TRH test negatively correlated with negative disorganization symptoms and with basal prolactin. The latter correlation suggests the contribution of factors related to maximal prolactin stimulation by TRH; therefore, an alternative dose of 6.25 μg TRH could be used for the mini-TRH test in first-episode patients, allowed by increased sensitivity of the present prolactin tests. Future studies are needed to investigate whether the mini-TRH test could help in finding the optimal antipsychotic medication.

Keywords

mini-TRH test - dopamine - prolactin - schizophrenia - extrastriatal

Publication History

Received: 04 October 2022
Received: 05 November 2022

Accepted: 10 November 2022

Article published online:
09 December 2022

• References

• 1 Freeman ME, Kanyicska B, Lerant A. et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-1631
• 2 Leong DA, Frawley LS, Neill JD. Neuroendocrine control of prolactin secretion. Annu Rev Physiol 1983; 45: 109-127
• 3 Hentschel K, Fleckenstein AE, Toney TW. et al. Prolactin regulating of tuberoinfundibular dopamine neurons: Immunoneutralization studies. Brain Res 2000; 852: 28-36
• 4 Spoov J. Submaximal plasma prolactin response to TRH and dopamine activity in man. Pharmacopsychiatry 1985; 18: 330-332
• 5 Burrow GN, May PB, Spaulding SW. et al. TRH and dopamine interactions affecting pituitary hormones secretion. J Clin Endocrinol Metab 1977; 45: 65-72
• 6 Norman RL, Quadri SK, Spies HG. Differential sensitivity of prolactin release to dopamine and thyrotrophin-releasing hormone in intact and pituitary stalk-sectioned rhesus monkeys. J Endocrinol 1980; 84: 479-487
• 7 Hill-Samli M, MacLeod RM. Interaction of thyrotropin-releasing hormone and dopamine on the release of prolactin from the rat anterior pituitary in vitro. Endocrinology 1974; 95: 1189-1192
• 8 Gary KA, Sevarino KA, Yarbrough GG. et al. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: Implications for TRH-based therapeutics. J Pharmacol Exp Ther 2003; 305: 410-416
• 9 Kineman RD, Gettys TW, Frawley LS. Role of guanine nucleotide-binding proteins, Gi alpha 3 and Gs alpha, in dopamine and thyrotropin-releasing hormone signal transduction: Evidence for competition and commonality. J Endocrinol 1996; 148: 447-455
• 10 Papenberg G, Karalija N, Salami A. et al. Balance between transmitter availability and dopamine D2 receptors in prefrontal cortex influences memory functioning. Cereb Cortex 2020; 30: 989-1000
• 11 Langer G, Sachar EJ, Halpern FS. et al. The prolactin response to neuroleptic drugs. A test of dopaminergic blockade: Neuroendocrine studies in normal men. J Clin Endocrinol Metab 1977; 45: 996-1002
• 12 Corenblum B, Taylor PJ. Mechanisms of control of prolactin release in response to apprehension stress and anesthesia-surgery stress. Fertil Steril 1981; 36: 712-715
• 13 Spoov J, Karonen SL. Urinary HVA reflects central dopamine activity in man. New Trends Exp Clin Psychiat 1987; 3: 93-99
• 14 Sassin JF, Frantz AG, Weitzman ED. et al. Human prolactin: 24-hour pattern with increased release during sleep. Science 1972; 177: 1205-1207
• 15 Rastogi GK, Dash RJ, Sharma BR. et al. Circadian responsiveness of the hypothalamic-pituitary axis. J Clin Endocrinol Metab 1976; 42: 798-803
• 16 Roelfsema F, Pijl H, Keenan DM. et al. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One 2012; 7: e31305 Published 2012 Feb 17
• 17 Karoum F, Karson CN, Bigelow LB. et al. Preliminary evidence of reduced combined output of dopamine and its metabolites in chronic schizophrenia. Arch Gen Psychiatry 1987; 44: 604-607
• 18 Dussault JH. The effect of dexamethasone on TSH and prolactin secretion after TRH stimulation. Can Med Assoc J 1974; 111: 1195-1197
• 19 Spoov J, Bredbacka PE, Appelberg B. et al. Prolactin response to submaximal stimulation by TRH in nonaffective psychoses. Biol Psychiatry 1991; 29: 204-210
• 20 Spoov J, Bredbacka PE, Stenman UH. An abnormal relation between basal prolactin levels and prolactin response to 12.5 microg TRH i. v. in drug-naïve patients with first-episode schizophrenia. Schizophr Res 2010; 119: 41-46
• 21 Spoov J, Bredbacka PE. Failing memory in nonaffective psychosis and prolactin response to 12.5 µg i. v. TRH. Pharmacopsychiatry 2021; 54: 246-247
• 22 Tsuchiya K. Studies on prolactin in major psychoses--with reference to prolactin response to stress in schizophrenia. Folia Psychiatr Neurol Jpn 1984; 38: 53-56
• 23 Carlson HE, Wasser HL, Levin SR. et al. Prolactin stimulation by meals is related to protein content. J Clin Endocrinol Metab 1983; 57: 334-338
• 24 Spoov J. Plasma prolactin response to submaximal stimulation by TRH and endogenous corticosteroids in man. Pharmacopsychiatry 1987; 20: 96-98
• 25 Muck-Seler D, Pivac N, Mustapic M. et al. Platelet serotonin and plasma prolactin and cortisol in healthy, depressed and schizophrenic women. Psychiatry Res 2004; 127: 217-226
• 26 Spoov J, Bredbacka PE, Stenman UH. Separation of hallucinations from other positive symptoms by prolactin response to 12.5 μg i. v. TRH (mini-TRH test). Schizophr Res 2020; 220: 287-288
• 27 Taylor AD, Philip JG, John CD. et al. Annexin 1 (lipocortin 1) mediates the glucocorticoid inhibition of cyclic adenosine 3’,5’-monophosphate-stimulated prolactin secretion. Endocrinology 2000; 141: 2209-2219
• 28 Maes M, Vandewoude M, Maes L. et al. A revised interpretation of the TRH test results in female depressed patients. Part II: Prolactin responses. Relationships with sex hormones, corticosteroid state, age, monoamines and amino acid levels. J Affect Disord 1989; 16: 215-221
• 29 Bagdy G, Arató M, Baraczka K. et al. Comparative analysis of indices of central dopaminergic functions in man. Life Sci 1983; 32: 2667-2676
• 30 Genazzani AD, Petraglia F, Volpogni C. et al. The duration of prolactin secretory bursts from the pituitary is independent from both prolactin and gonadal steroid plasma levels in women and in men. J Endocrinol Invest 1994; 17: 83-89
• 31 Muti P, Trevisan M, Micheli A. et al. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 1996; 5: 917-922
• 32 Tuckwell HC, Koziol JA. A meta-analysis of homovanillic acid concentrations in schizophrenia. Int J Neurosci 1993; 73: 109-114
• 33 Stanley M, Traskman-Bendz L, Dorovini-Zis K. Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 1985; 37: 1279-1286
• 34 Slifstein M, van de Giessen E, Van Snellenberg J. et al. Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study. JAMA Psychiatry 2015; 72: 316-324
• 35 Fountoulakis KN, Dragioti E, Theofilidis AT. et al. Staging of schizophrenia with the use of PANSS: An international multi-center study. Int J Neuropsychopharmacol 2019; 22: 681-697
• 36 Davis BM, Davis KL, Mohs RC. et al. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. Arch Gen Psychiatry 1985; 42: 259-264
• 37 Pickar D, Breier A, Hsiao JK. et al. Cerebrospinal fluid and plasma monoamine metabolites and their relation to psychosis. Implications for regional brain dysfunction in schizophrenia. Arch Gen Psychiatry 1990; 47: 641-648
• 38 Anand I, Sunitha TA, Khanna S. CSF amines and their metabolites in first episode drug naïve schizophrenic patients and their correlations with dimensions of schizophrenia. Indian J Psychiatry 2002; 44: 212-219
• 39 Malinowski FR, Tasso BC, Ortiz BB. et al. Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis. Braz J Psychiatry 2020; 42: 22-26
• 40 Post RM, Fink E, Carpenter WT. et al. Cerebrospinal fluid amine metabolites in acute schizophrenia. Arch Gen Psychiatry 1975; 32: 1063-1069
• 41 Loch AA. Schizophrenia, not a psychotic disorder: Bleuler revisited. Front Psychiatry 2019; 10: 328
• 42 Smith B, Fowler DG, Freeman D. et al. Emotion and psychosis: Links between depression, self-esteem, negative schematic beliefs and delusions and hallucinations. Schizophr Res 2006; 86: 181-188
• 43 Epstein J, Stern E, Silbersweig D. Mesolimbic activity associated with psychosis in schizophrenia. Symptom-specific PET studies. Ann N Y Acad Sci 1999; 877: 562-574
• 44 Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: Relationship to illness phases. Biol Psychiatry 1999; 46: 56-72
• 45 Rausch F, Mier D, Eifler S. et al. Reduced activation in ventral striatum and ventral tegmental area during probabilistic decision-making in schizophrenia. Schizophr Res 2014; 156: 143-149
• 46 Rajkumar RP. Prolactin and psychopathology in schizophrenia: A literature review and reappraisal. Schizophr Res Treatment 2014; 2014: 175360
• 47 Fennig S, Mottes A, Ricter-Levin G. et al. Everyday memory and laboratory memory tests: General function predictors in schizophrenia and remitted depression. J Nerv Ment Dis 2002; 190: 677-682
• 48 Wallwork RS, Fortgang R, Hashimoto R. et al. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res 2012; 137: 246-250
• 49 Spoov J, Bredbacka PE, Stenman UH. Separation of positive and disorganization symptoms by prolactin response to 12.5 μg intravenous TRH. Schizophr Res 2020; 215: 449-450
• 50 White L, Harvey PD, Opler L. et al. Empirical assessment of the factorial structure of clinical symptoms in schizophrenia. Psychopathology 1997; 30: 263-274
• 51 Hwang K, Bertolero MA, Liu WB. et al. The human thalamus is an integrative hub for functional brain networks. J Neurosci 2017; 37: 5594-5607
• 52 Cheng W, Palaniyappan L, Li M. et al. Voxel-based, brain-wide association study of aberrant functional connectivity in schizophrenia implicates thalamocortical circuitry. NPJ Schizophr 2015; 1: 15016
• 53 Cao H, Chén OY, Chung Y. et al. Cerebello-thalamo-cortical hyperconnectivity as a state-independent functional neural signature for psychosis prediction and characterization. Nat Commun 2018; 9: 3836
• 54 Tremblay LK, Naranjo CA, Graham SJ. et al. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatry 2005; 62: 1228-1236
• 55 Ogawa S, Tsuchimine S, Kunugi H. Cerebrospinal fluid monoamine metabolite concentrations in depressive disorder: A meta-analysis of historic evidence. J Psychiatr Res 2018; 105: 137-146
• 56 Westerink BH, Kawahara Y, De Boer P. et al. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur J Pharmacol 2001; 412: 127-138
• 57 Moreines JL, Owrutsky ZL, Gagnon KG. et al. Divergent effects of acute and repeated quetiapine treatment on dopamine neuron activity in normal vs. chronic mild stress induced hypodopaminergic states. Transl Psychiatry 2017; 7: 1275